Abstract
The C3 convertases are the major proteases of the complement cascade and are assembled at the site of complement activation via several different pathways. Properdins functional role in stabilizing the alternative pathway convertase has been long established; however, new evidence demonstrates that properdin can also bind to certain microbial surfaces, and provide a platform for de novo convertase assembly. Therefore, properdin participates in two distinct mechanisms for complement activation: the alternative pathway and a properdin-directed pathway. Previous work had implicated the alternative pathway in the initiation and/or progression of several autoimmune diseases and in the host defense against certain bacterial pathogens. Those conclusions were based on evidence that cannot distinguish effects of the alternative pathway from effects of the properdin-directed pathway. With the identification of the new role for properdin in C3 convertase assembly there became a pressing need to reassess the mechanisms of complement activation, determine the specific role of properdin in each of these pathways, and explore the new therapeutic avenues that could arise.
Keywords: Properdin, complement, C3 convertase, innate immunity, Neisseria, alternative pathway, properdin-directed pathway
Current Drug Targets
Title: Properdin and Complement Activation: A Fresh Perspective
Volume: 9 Issue: 2
Author(s): Dennis E. Hourcade
Affiliation:
Keywords: Properdin, complement, C3 convertase, innate immunity, Neisseria, alternative pathway, properdin-directed pathway
Abstract: The C3 convertases are the major proteases of the complement cascade and are assembled at the site of complement activation via several different pathways. Properdins functional role in stabilizing the alternative pathway convertase has been long established; however, new evidence demonstrates that properdin can also bind to certain microbial surfaces, and provide a platform for de novo convertase assembly. Therefore, properdin participates in two distinct mechanisms for complement activation: the alternative pathway and a properdin-directed pathway. Previous work had implicated the alternative pathway in the initiation and/or progression of several autoimmune diseases and in the host defense against certain bacterial pathogens. Those conclusions were based on evidence that cannot distinguish effects of the alternative pathway from effects of the properdin-directed pathway. With the identification of the new role for properdin in C3 convertase assembly there became a pressing need to reassess the mechanisms of complement activation, determine the specific role of properdin in each of these pathways, and explore the new therapeutic avenues that could arise.
Export Options
About this article
Cite this article as:
Hourcade E. Dennis, Properdin and Complement Activation: A Fresh Perspective, Current Drug Targets 2008; 9 (2) . https://dx.doi.org/10.2174/138945008783502458
DOI https://dx.doi.org/10.2174/138945008783502458 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances for Cell / Gene Therapy in Rheumatoid Arthritis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Synthetic Peptides in the Diagnosis of Neurological Diseases
Current Protein & Peptide Science Regulation of B-Cell Activation by Complement Receptors CD21 and CD35
Current Pharmaceutical Design Immunomodulatory Activity of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy α-Galactosylceramide: Potential Immunomodulatory Activity and Future Application [General Articles]
Current Medicinal Chemistry Use of Mesenchymal Stem Cells in Crohn's Disease and Perianal Fistulas: A Narrative Review
Current Stem Cell Research & Therapy Gene Therapy Using IL-12 Family Members in Infection, Auto-Immunity, and Cancer
Current Gene Therapy Apoptosis and Autoimmune Disease
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Serological Electrodetection of Rheumatoid Arthritis Using Mimetic Peptide
Protein & Peptide Letters Celastrol and Terpenes as Anti-Infective Agents
Anti-Infective Agents in Medicinal Chemistry Potential Use of Drugs that Target Neural-Immune Pathways in the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Cyclooxygenase-2 Inhibitors as a Therapeutic Target in Inflammatory Diseases
Current Medicinal Chemistry Preface [Hot Topic: Transcription Factors as Targets of Novel Therapeutic Approaches of Autoimmune Diseases (Executive Editor: Gunther Ne)]
Current Pharmaceutical Design Effects of Secondhand Smoke on Thyroid Function
Inflammation & Allergy - Drug Targets (Discontinued) Migraine in Systemic Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Small Molecular Inhibitors for the Treatment of Rheumatoid Arthritis: Progress so Far
Mini-Reviews in Medicinal Chemistry Pharmacokinetic and Toxicological Characteristics of Tripterigium Glycosides and Their Derivatives
Current Drug Metabolism Impact of Hydroxyl Radical Modified-Human Serum Albumin Autoantigens in Systemic Lupus Erythematosus
Current Protein & Peptide Science Use of MHC II Structural Features in the Design of Vaccines for Organ-Specific Autoimmune Diseases
Current Pharmaceutical Design Control of Autoimmune Diseases by the B7-CD28 Family Molecules
Current Pharmaceutical Design